Alpha-ketoglutarate
A central metabolic intermediate with mouse healthspan findings and unfinished human geroscience questions.
Status database
Search peptides and related molecules by name, topic, FDA status, evidence level, and entity type, then open the full source-backed page when a row matters.
Showing 48 of 48 entries
Every row links to the full source-backed page
A central metabolic intermediate with mouse healthspan findings and unfinished human geroscience questions.
An experimental synthetic peptide popular online despite very limited reliable human evidence.
A melanocortin-receptor peptide approved for a narrowly defined sexual-desire disorder.
An investigational long-acting amylin analog studied alone and with semaglutide for obesity and type 2 diabetes.
An unapproved growth hormone-releasing hormone analog with limited human data.
A well-studied performance supplement with credible muscle evidence and a less certain cognitive-aging frontier.
An experimental senolytic pairing that combines a serious cancer medicine with a flavonoid.
A mitochondria-targeting peptide with an accelerated FDA approval for a narrow Barth syndrome indication.
An FDA-approved diabetes peptide whose promising Phase 2 Parkinson signal failed in a larger Phase 3 trial.
A plant flavonoid with striking mouse senolytic findings but no proven human longevity or frailty benefit.
A copper-binding tripeptide used in cosmetic research, with mostly laboratory and animal wound-healing evidence.
An unapproved ghrelin-receptor agonist that raises growth hormone and appetite without proven muscle-building outcomes.
A mitochondrial-derived peptide studied for cell survival, neuroprotection, metabolism, and aging mostly in preclinical work.
An unapproved growth hormone secretagogue with limited clinical evidence and FDA-identified concerns.
Compounds that raise circulating ketones reliably but have not established cognitive or healthy-aging benefit.
A reproductive signaling peptide studied in fertility, hormone release, and brain responses.
A minimally absorbed peptide medicine approved for several constipation disorders in defined adult and pediatric populations.
An established GLP-1 medicine approved for specific diabetes and weight-management uses.
A discontinued U.S. GLP-1 product with established diabetes evidence and an encouraging but unconfirmed Parkinson trial.
A foundational diabetes medicine being studied in geroscience, without an approved anti-aging use.
A mitochondrial-derived peptide with intriguing metabolic and exercise biology but no proven human therapy.
A central cellular coenzyme with legitimate biology but little clinical-outcomes evidence for wellness infusions.
An NAD+ precursor with small human trials and unresolved real-world clinical value.
An NAD+ precursor that reliably changes biomarkers but has not shown a consistent anti-aging or cognitive benefit.
A natural peptide hormone with approved obstetric products and unproven intranasal cognitive or social uses.
An investigational glucagon/GLP-1 dual agonist in mid-stage research for MASH, liver fat, and obesity.
An FDA-approved gut-signaling peptide for chronic idiopathic constipation and IBS with constipation in adults.
An FDA-approved amylin analog for selected insulin-treated diabetes patients, with unapproved weight-management research.
An investigational triple-receptor agonist in Phase 3 clinical trials.
An investigational hepcidin-mimetic peptide under FDA priority review for polycythemia vera.
An unapproved synthetic heptapeptide studied for anxiety, with a thin and uncertain human evidence base.
A GLP-1 medicine with FDA-approved products for type 2 diabetes and chronic weight management.
An unapproved neuroactive heptapeptide with old, small human studies and substantial evidence gaps.
A growth hormone-releasing hormone analog whose former FDA-approved product was discontinued.
An MC4-receptor peptide medicine approved for obesity caused by specific rare genetic conditions.
An FDA-approved immunosuppressant with serious risks and unproven longevity use in healthy people.
A food-derived polyamine linked to autophagy biology, with a negative phase 2 cognitive primary outcome.
An investigational glucagon/GLP-1 dual agonist in Phase 3 research for obesity and metabolic liver disease.
A common nutrient-related molecule whose animal longevity story is challenged by human aging data.
An FDA-approved GLP-2 analog that improves intestinal absorption in short bowel syndrome dependent on parenteral support.
A growth hormone-releasing factor analog approved for a narrow HIV-related indication.
An immune-modulating peptide used in some countries but not FDA approved for any U.S. indication.
A naturally occurring peptide studied in tissue repair; marketed fragments are not FDA approved.
A dual GIP/GLP-1 receptor agonist approved for specific metabolic and sleep-apnea uses.
An FDA-approved synthetic peptide analog for Rett syndrome with modest trial benefits and frequent gastrointestinal adverse effects.
A mitophagy-related metabolite with human biomarker and muscle-endurance signals but no approved disease use.
A C-type natriuretic peptide analog approved to increase growth in children with achondroplasia.
A cone-snail-inspired peptide medicine approved for severe chronic pain under specialist care.